Literature DB >> 6581863

Estrone and dehydroepiandrosterone sulfatase activities and plasma estrone sulfate levels in human breast carcinoma.

O Prost, M O Turrel, N Dahan, C Craveur, G L Adessi.   

Abstract

The activity of the two membrane-bound sulfatases, estrone and dehydroepiandrosterone sulfatases, are reported in human breast carcinoma tissues. In 21 tested tumors (12 from post-menopausal women and 9 from nonmenopausal women), the two sulfatases were consistently present. The apparent Km values for estrone and dehydroepiandrosterone sulfatases were, respectively, 6.8 and 14.9 microM. In terms of maximal velocity, the sulfatase activities are not correlated to the estrogen or progesterone receptor status of the tumors or to the hormonal status of the donors. It may be concluded that these two activities are not hormone dependent. Estrone sulfate, the substrate of estrone sulfatase, has been measured in plasma of postmenopausal women. The mean levels (nmol/liter) of plasma estrone sulfate were compared in post-menopausal women with (n = 51) or without (n = 39) breast cancer. For the first age group (48 to 55 years old), no statistically significant difference in these levels was observed [1.91 +/- 1.06 versus 1.50 +/- 1.04 (mean +/- t0.95 (Formula: see text) S.E.)]. For the two other age groups (56 to 65 and 66 to 80 years of age), the differences were statistically significant [1.46 +/- 0.43 versus 0.77 +/- 0.21 (p less than 0.02) and 1.77 +/- 0.53 versus 0.81 +/- 0.22 (p less than 0.01)]. The usefulness of plasma estrone 3-sulfate levels as an indicator of the real estrogen status of postmenopausal women is discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6581863

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Enzymatic regulation of estradiol-17 beta concentrations in human breast cancer cells.

Authors:  J B Adams
Journal:  Breast Cancer Res Treat       Date:  1992-03       Impact factor: 4.872

Review 2.  Could aminoglutethimide replace adrenalectomy?

Authors:  A L Harris
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

3.  Estrogen sulfates: biological and ultrastructural responses and metabolism in MCF-7 human breast cancer cells.

Authors:  J R Pasqualini; C Gelly; F Lecerf
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

4.  Oestrone sulphate, adipose tissue, and breast cancer.

Authors:  R A Hawkins; M L Thomson; E Killen
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

5.  beta-Glucuronidase levels in patients with fibrocystic breast disease.

Authors:  J P Minton; Z Walaszek; W Schooley; M Hanausek-Walaszek; T E Webb
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

6.  The effects of a low-fat dietary intervention and tamoxifen adjuvant therapy on the serum estrogen and sex hormone-binding globulin concentrations of postmenopausal breast cancer patients.

Authors:  D P Rose; J M Connolly; R T Chlebowski; I M Buzzard; E L Wynder
Journal:  Breast Cancer Res Treat       Date:  1993-09       Impact factor: 4.872

7.  Estrone sulfatase activity and effect of antiestrogens on transformation of estrone sulfate in hormone-dependent vs. independent human breast cancer cell lines.

Authors:  J R Pasqualini; B L Nguyen
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

8.  Dehydroepiandrosterone concentration in breast cancer tissue is related to its plasma gradient across the mammary gland.

Authors:  E Brignardello; P Cassoni; M Migliardi; A Pizzini; M Di Monaco; G Boccuzzi; M Massobrio
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

9.  Dehydroepiandrosterone and estrone 17-ketosteroid reductases in MCF-7 human breast cancer cells.

Authors:  J H MacIndoe; M Hinkhouse; G Woods
Journal:  Breast Cancer Res Treat       Date:  1990-10       Impact factor: 4.872

10.  Evaluation of cytotoxic effects of several novel tetralin derivatives against Hela, MDA-MB-468, and MCF-7 cancer cells.

Authors:  Fateme Shafiee; Hojjat Sadeghi-Aliabadi; Farshid Hassanzadeh
Journal:  Adv Biomed Res       Date:  2012-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.